Outsmart
Your Disease™
ImmunityBio is developing cell and immunotherapy products that are designed to help strengthen each patient’s natural immune system, potentially enabling it to outsmart the disease and eliminate cancerous or infected cells.
Executive Chairman, ImmunityBio
At ImmunityBio, we envision a day when we no longer fear cancer, but are able to conquer it, thanks to the biological wonder that is the human immune system. Our scientists are working to develop remarkable new therapies that harness that inherent power by amplifying both branches of the immune system, attacking cancerous or infected cells today while building immunological memory for tomorrow. The goal: to reprogram the patient’s immune system and treat the host rather than just the disease.
Smart Therapies for Difficult Diseases™
Our investigational immunotherapy products are tailored to each patient’s needs. We employ a “triangle” offense designed to deliver durable, complete responses in cancer and infectious diseases.
Investigational Cancer Therapies
ImmunityBio’s platform addresses the entire immune system beyond the limitations of chimeric antigen receptor T-cell (CAR-T) therapies and checkpoint inhibitors by activating the natural killer cell, T cells, macrophages, and inducing memory through dendritic cells. Clinical trials orchestrating these unique therapies, which harness both the innate and adaptive immune system, are in progress across multiple tumor types.
Investigational Viral Therapies
Infected cells, like cancer cells, can be exposed to enable recognition and killing by our natural killer cell and T cell platforms. Current clinical trials addressing HIV, COVID, and infectious diseases are in progress. A second-generation human adenovirus (hAd5) vector serves as a platform to deliver specific viral sequences and educate our immune system to clear the infected cells. The potential to administer these vaccines orally will enable greater global access.
ImmunityBio is continuously pursuing new immunotherapies designed to attack disease by enhancing the patient’s immune system, not weakening it.
A Robust Clinical Pipeline
ImmunityBio's investigational immunotherapies are currently being studied for cancer and infectious diseases in a range of clinical trials at various stages.
Latest News & Events
ImmunityBio Announces Authorization to Proceed with Phase 1/2/3 Randomized Trial in South Africa of Their Dual-Antigen T-Cell Vaccine as a Universal Boost in Previously Vaccinated Participants Against COVID-19
The Phase 1/2/3 trial will study the efficacy, safety, and immunogenicity of ImmunityBio’s T-Cell COVID-19 vaccine as...
ImmunityBio and NantOmics Announce Clinical Validation of a Proprietary Method to Identify Unique Targets for Immunotherapy in Individual Breast Cancer Patients
The “neoepitope” identification pipeline facilitates discovery of immunotherapy targets unique to individual cancer...
FDA Authorizes ImmunityBio Study of Anktiva and PD-L1 t-haNK to Increase Effectiveness of Trodelvy in Triple-Negative Breast Cancer
Open-label Phase 1b/2 study will evaluate the safety and preliminary efficacy of Anktiva (N-803) and PD-L1 t-haNK in...